IDEAYA Biosciences
7000 Shoreline Court
Suite 350
South San Francisco
California
94080
United States
Tel: 650-443-6209
Website: http://www.ideayabio.com/
About IDEAYA Biosciences
Founded in 2015, IDEAYA Biosciences is a public, clinical-stage synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response.
Stock Symbol: IDYA
125 articles with IDEAYA Biosciences
-
IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022
11/29/2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics and participating key opinion leaders for its Investor R&D Day.
-
IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
11/28/2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Darrin M. Beaupre, M.D., Ph.D., has joined the company as its Chief Medical Officer, effective November 21, 2022.
-
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
11/8/2022
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2022.
-
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences - November 01, 2022
11/1/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in November 2022 and its plans to host an Investor R&D Day in December 2022.
-
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors
10/18/2022
IDEAYA Biosciences, Inc. announced clinical program updates for IDE397, an investigational, potential best-in-class, small molecule MAT2A inhibitor being evaluated in an ongoing Phase 1/2 clinical trial.
-
IDEAYA Announces Pricing of Public Offering of Common Stock - September 15, 2022
9/15/2022
IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of 7,619,048 shares of its common stock at a public offering price of $10.50 per share, before underwriting discounts and commissions.
-
IDEAYA Announces Proposed Public Offering of Common Stock - September 14, 2022
9/14/2022
IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $80.0 million of shares of its common stock in an underwritten public offering.
-
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
9/11/2022
IDEAYA Biosciences, Inc. announced interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma patients.
-
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
9/6/2022
IDEAYA Biosciences, Inc. announced that it has initiated an Investigator Sponsored Trial, or IST, in coordination with St. Vincent's Hospital, Sydney, to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma patients.
-
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
8/30/2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences and events in September 2022.
-
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
8/29/2022
IDEAYA Biosciences, Inc. announced that it has achieved a preclinical development milestone in connection with ongoing IND-enabling studies for its Pol Theta Helicase Development Candidate.
-
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
8/15/2022
IDEAYA Biosciences, Inc. provided a business update and announced financial results for the second quarter ended June 30, 2022.
-
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
7/27/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, an investigational, potential best-in-class, small molecule MAT2A inhibitor being evaluated in an ongoing Phase 1/2 clinical trial.
-
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
7/27/2022
IDEAYA Biosciences, Inc. announced it has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397, its investigational, potential best-in-class, small molecule MAT2A inhibitor, with Amgen's AMG 193, an investigational small molecule MTA-cooperative inhibitor of PRMT5, in a Phase 1 clinical trial.
-
IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
6/28/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a potential first-in-class Pol Theta Helicase development candidate.
-
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
6/8/2022
IDEAYA Biosciences, Inc. announced its participation at the 2022 Jefferies Global Healthcare Conference.
-
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
5/10/2022
IDEAYA Biosciences, Inc. provided a business update and announced financial results for the first quarter ended March 31, 2022.
-
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
5/3/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in May 2022.
-
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
5/2/2022
IDEAYA Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan-drug designation to darovasertib, a potential first-in-class protein kinase C inhibitor, for the treatment of uveal melanoma.
-
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors
4/6/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.